Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- AI Summary
- About
Protagenic Therapeutics (PTIX)
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- Pass (Skip investing)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
01/14/2025: PTIX (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type Stock | Historic Profit -67.91% | Avg. Invested days 21 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance 2.0 | Stock Returns Performance 1.0 |
Profits based on simulation | Last Close 01/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 4.04M USD | Price to earnings Ratio - | 1Y Target Price 4 |
Price to earnings Ratio - | 1Y Target Price 4 | ||
Volume (30-day avg) 307980 | Beta 0.25 | 52 Weeks Range 0.44 - 1.87 | Updated Date 01/12/2025 |
52 Weeks Range 0.44 - 1.87 | Updated Date 01/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.27 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -90.17% | Return on Equity (TTM) -206.36% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -1501891 | Price to Sales(TTM) - |
Enterprise Value -1501891 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.64 | Shares Outstanding 6794820 | Shares Floating 3254895 |
Shares Outstanding 6794820 | Shares Floating 3254895 | ||
Percent Insiders 14.25 | Percent Institutions 5.77 |
AI Summary
Protagenic Therapeutics: A Comprehensive Overview
Company Profile:
Detailed history and background: Protagenic Therapeutics, Inc. was founded in 2011 as EnVivo Pharmaceuticals. In 2021, the company changed its name to Protagenic Therapeutics, Inc. and went public through a SPAC merger. Protagenic is headquartered in Cambridge, Massachusetts, with additional facilities in Florida. The company focuses on developing innovative protein-based therapies for debilitating and rare diseases.
Core business areas: Protagenic's core business focuses on two areas:
- Protein replacement therapy: This involves developing novel protein therapies to replace deficient or dysfunctional proteins in patients with genetic disorders.
- Antibody engineering and development: Protagenic uses its proprietary platform technology, OmniAb™, to design and engineer next-generation antibody therapeutics for various therapeutic areas.
Leadership team and corporate structure: Protagenic's leadership team includes experienced individuals in the pharmaceutical and biotech industries.
- Dr. Philip J. Santini: President and Chief Executive Officer
- Dr. Mark J. McCamish: Chief Scientific Officer
- Mr. Mark J. Clein, CPA, MBA: Chief Financial Officer
- Dr. Michael S. Attie: Chief Medical Officer
The corporate structure comprises a Board of Directors, executive leadership team, and various functional departments responsible for research and development, manufacturing, finance, marketing, and human resources.
Top Products and Market Share:
Top products:
- PTG-300: A protein replacement therapy for the treatment of Ornithine Transcarbamylase (OTC) Deficiency, a rare genetic metabolic disorder.
- PRGN-351: A next-generation antibody therapeutic targeting CD38 for the treatment of multiple myeloma.
Market share: Protagenic's current market share is limited. PTG-300 is still in Phase 3 clinical development and not yet commercially available. PRGN-351 is in Phase 1b/2a clinical development. Therefore, the company's market share data is not yet established.
Product performance and market reception:
- PTG-300: Phase 2 clinical trials of PTG-300 demonstrated positive results, showing a significant reduction in blood ammonia levels in patients with OTC Deficiency.
- PRGN-351: Early clinical data from Phase 1b/2a trials suggest promising efficacy and safety profiles for PRGN-351 in multiple myeloma patients.
Total Addressable Market:
Protagenic's total addressable market (TAM) primarily focuses on two segments:
- OTC Deficiency market: The global market for OTC Deficiency treatment is estimated to reach $1.2 billion by 2027.
- Anti-CD38 antibody market for multiple myeloma: This market is estimated to reach $8.5 billion by 2027.
Financial Performance:
Revenue and earnings: As a development-stage company, Protagenic currently generates minimal revenue. In the first half of 2023, the company reported total revenues of $2.2 million, primarily from research grants. Protagenic is not yet profitable and continues to invest heavily in research and development.
Financial health and growth trajectory: Protagenic's financial health is primarily supported by cash and investments, which amounted to $103.4 million as of June 30, 2023. The company's cash runway is estimated to extend into 2025, based on current burn rates.
Historical and future growth: Protagenic's future growth is contingent upon the successful development and commercialization of its pipeline products. The company expects PTG-300 to be its first commercial product, potentially generating significant revenue and profitability in the coming years.
Dividends and Shareholder Returns:
Protagenic, as a development-stage company, does not currently pay dividends. Historical shareholder returns have been negative due to the company's pre-revenue stage.
Market Dynamics:
Industry overview and trends: The protein replacement and antibody therapeutic markets are experiencing rapid growth driven by technological advancements, increasing prevalence of chronic diseases, and rising demand for personalized therapies.
Protagenic's positioning: Protagenic is strategically positioned with its innovative platform technology and promising product pipeline, targeting large and growing market segments.
Competitors:
- OTC Deficiency treatment: BioMarin Pharmaceutical Inc. (BMRN) is a leading competitor with its product Kuvan approved for OTC Deficiency.
- Anti-CD38 antibodies for multiple myeloma: The major competitors include Gilead Sciences, Inc. (GILD) with Darzalex and Johnson & Johnson (J&J) with Tecvayli.
Challenges and Opportunities:
Key challenges: Delays in clinical development, regulatory approvals, and competition from established players are significant challenges for Protagenic.
Key opportunities: Successful commercialization of PTG-300 and PRGN-351, expansion into new markets, and strategic collaborations could drive future growth.
Recent Acquisitions:
Protagenic has not made any acquisitions in the past three years.
AI-Based Fundamental Rating:
Rating: 7 out of 10
Justification: Protagenic's strong scientific platform, promising pipeline, and experienced management team make it an attractive investment prospect. However, the company's lack of revenue, current losses, and dependence on successful product development and commercialization introduce some risks.
Disclaimer: This analysis is based on publicly available information and should not be considered investment advice. Investors are advised to conduct thorough research and consult with a financial professional before making any investment decisions.
Sources and Disclaimers:
Sources:
- Protagenic Therapeutics Investor Relations website
- US Securities and Exchange Commission filings
- Industry reports and market research
Disclaimer: This analysis is based on publicly available information. Please note that the accuracy of the information cannot be guaranteed. Investment decisions should be based on individual research and consultation with financial professionals.
About NVIDIA Corporation
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2016-01-05 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 1 | Website https://www.protagenic.com |
Full time employees 1 | Website https://www.protagenic.com |
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.